2.71 USD
▲+0.07+5.25%
盘后 2.58 +0.19%
2026-08-03
市值
$60.76M
市盈率
—
EPS
-2.50
股息率
—
52 周区间
0.96 – 2.79
成交量
377.26K
Beta
0.40
目标价
—
52W 低 0.9652W 高 2.79
价格走势
公司简介
Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company was formerly known as Pretzel ...